NEW YORK, March 3 (GenomeWeb News) -- Intrexon Corporation has closed a $1 million round of private-equity financing to advance its subcellular tools and related marketing initiatives, the company said this week.
"This financing will enable us to expand our capabilities and offerings in the emerging market for subcellular inhibition tools," Robert Beech, Intrexon's CEO said in a statement.
The financing was provided by NewVa Capital Partners, a regional investment partnership managed by Third Security. NewVa last made an investment in Intrexon in May 2005.
Intrexon has used previous investment funds to research, develop, and validate a set of DNA vectors that target selected kinases in primary subcellular locations. These vectors are now available from the company as mDECOY kits, Intrexon said.